Accelerating Biologics Development with a High-Concentration Formulation Platform

Explore how Altruist’s Altru-CON platform addresses high-concentration formulation challenges and discover a data-driven approach to stable, low-viscosity formulations that can accelerate development and enable more patient-friendly delivery options.

Register Free: https://www.pharmtech.com/pt_w/accelerating-biologics

Event Overview:

As the global biologics industry advances toward higher drug concentrations and more patient-friendly delivery formats, Altruist Biologics’ Altru-CON™ platform delivers dual breakthroughs in both concentration and stability. Powered by a high-throughput screening approach and an intelligent excipient optimization system incorporating more than 40 buffer systems and 30 excipient combinations, this structured development approach enhances candidate selection, reduces late-stage reformulation risk, and improves overall probability of success. This new platform enables stable formulations ranging from 100 to over 220 mg/mL, while maintaining a low viscosity suitable for subcutaneous administration.

Key Learning Objectives:

• Understand the key market drivers and formulation challenges in high-concentration
• Explore the unique featured of Altruist Biologics' Altru-CON^TM platform
• Apply high-throughput screening and intelligent excipient libraries to enable table formulations
• Learn how high-concentration biologics empower life cycle management

Who Should Attend:

• Biotech and biopharma CSOs or heads of science seeking innovative solutions for developing biologics formulations
• Pharmaceutical formulation scientists/developers looking to optimize performance and consistency in workflows
• Process development scientists and engineers involved in scaling and improving bioprocessing efficiency
• Outsourcing managers for contract development and manufacturing, academics/researchers in pharmaceutical sciences, and business development leads
• Any individual involved in the analysis, development, manufacturing, and quality control of biopharmaceutical products

Speaker:

Mingyang Hei. PhD
Director, Drug Product Development
Altruist Biologics

Mingyang Hei, PhD, is the drug product development director at Altruist Biologics with over 8 years of specialized experience in biopharmaceutical formulation development. He possesses extensive technical and leadership expertise across the entire product life cycle, having contributed to 2 FDA BLA approvals, 2 EMA market approvals, and 6 NMPA NDA/BLA submissions, with over 50 IND filings and multiple postmarket life cycle management deliveries.

Hei led the establishment of an end-to-end formulation platform spanning early-stage developability assessment through late-stage development to support global regulatory registration. His technical portfolio covers a diverse spectrum of modalities, including monoclonal antibodies (mAbs), multispecific antibodies (bispecific to tetraspecific), antibody conjugates, peptides, and oligonucleotides. He has led the team to build industry-leading capabilities in high-concentration formulation development, drug-device combination products, and co-formulation development.

Register Free: https://www.pharmtech.com/pt_w/accelerating-biologics